Biopharma Service Providers Address a Full Plate of Challenges

Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.

Participants in this discussion included: Don Paul Kovarcik, technical marketing specialist, Ajinomoto Althea; Robert H. DeWit, president of MPI Research; John Allinson, head of biomarker strategy, drug development services at LGC; Michael Lehmann, president, global sales and marketing, Patheon; Brian Hampson, vice-president, global manufacturing sciences and technology, PCT, a Caladrius Company; Fiona Greer, global director, BioPharma Services Development–Life Sciences, SGS; and Peter Soelk, managing director, Vetter Pharma International.

Download the

.